As per attachment.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 2.1 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Norris Medicines Ltd reported audited results for FY25 with revenue from operations of Rs. 582.02 lakhs (vs Rs. 563.56 lakhs in FY24), a modest ~3% growth. However, the company slipped deeper into losses with a loss after tax of Rs. 123.75 lakhs (vs Rs. 118.68 lakhs loss last year). Q4 alone saw revenue jump sharply to Rs. 272.09 lakhs but also recorded a quarterly loss of Rs. 22.85 lakhs. The auditor issued an unmodified opinion but included an Emphasis of Matter paragraph. Worryingly, the balance sheet shows negative total equity of Rs. 1,486.75 lakhs (other equity at Rs. -2,479.33 lakhs) and non-current borrowings of Rs. 1,852.74 lakhs, indicating a deeply stressed capital structure. Operating cash flow was positive at Rs. 29.85 lakhs.
Shareholders should note that the company continues to report losses and its net worth is negative, raising serious going-concern concerns. The negative book value and accumulated losses may weigh on the stock; investors should watch for any signs of restructuring, fund infusion, or asset sales.